sr141716 has been researched along with Psychotic Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheer, JF; Glick, SD; Morra, JT | 1 |
| Arvanitis, L; Bauer, D; Meltzer, HY; Rein, W | 1 |
1 trial(s) available for sr141716 and Psychotic Disorders
| Article | Year |
|---|---|
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cannabinoids; Double-Blind Method; Drugs, Investigational; Female; Haloperidol; Humans; Male; Middle Aged; Neurotensin; Peptide Fragments; Piperidines; Placebos; Psychotic Disorders; Pyrazoles; Pyrrolidonecarboxylic Acid; Receptors, Neurokinin-3; Research Design; Rimonabant; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2004 |
1 other study(ies) available for sr141716 and Psychotic Disorders
| Article | Year |
|---|---|
Cannabinoid receptors mediate methamphetamine induction of high frequency gamma oscillations in the nucleus accumbens.
Topics: Animals; Brain Waves; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Central Nervous System Stimulants; Disease Models, Animal; Dose-Response Relationship, Drug; Interneurons; Male; Methamphetamine; Nerve Tissue Proteins; Neurotoxicity Syndromes; Nucleus Accumbens; Piperidines; Psychomotor Performance; Psychotic Disorders; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptors, Cannabinoid; Rimonabant | 2012 |